Ads
related to: bicalutamide and prostate cancer- Oral Medication
Learn More About An Oral Treatment
For Metastatic Prostate Cancer.
- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Genomic Testing
Read How Testing Could
Help Inform Your Treatment Plan.
- Patient Support Program
Learn About A Treatment Option
And Patient Support.
- Oral Medication
Search results
Results From The WOW.Com Content Network
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
[45] [46] Moreover, the lifetime incidence of breast cancer in men is approximately 0.1%, [47] the average age of diagnosis of prostate cancer and male breast cancer are similar (around 70 years), [10] [48] and millions of men have been treated with bicalutamide for prostate cancer, [49] all of which are potentially in support of the notion of ...
Bicalutamide has been found to be at least as effective as or more effective than flutamide in the treatment of prostate cancer, [38] [39] and is considered to be the most potent and efficacious antiandrogen of the three first-generation NSAAs. [82]
Men with prostate cancer treated with bicalutamide are relatively elderly. [108] The increases in testosterone levels with NSAAs like flutamide and bicalutamide may result in greater absolute levels of testosterone and estradiol in younger men than in older men. [109]
1995: Bicalutamide is first introduced for medical use, to treat prostate cancer [207] 1996: Nilutamide is first introduced for medical use in the United States, to treat prostate cancer [ 240 ] 2006: The second-generation nonsteroidal antiandrogen enzalutamide is first described [ 241 ]
Ads
related to: bicalutamide and prostate cancer